| 靶点: |
IC50: 0.1 nM (Phosphodiesterase 10A) |
| 体内研究: |
AMG 579 shows statistically significant reduction of PCP induced behavior in rats over the 2 h period. Minimum effective doses for efficacy in PCP-LMA model is determined to be 0.3 mg/kg for AMG 579. In dog, 5 exhibits superior oral bioavailability of 72%. |
| 参考文献: |
1. Hu E,et al. Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A). J Med Chem. 2014 Aug 14;57(15 |
| 保存条件: |
-80℃(运输条件:冰袋低温运输) |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.265 ml |
11.326 ml |
22.651 ml |
| 5 mM |
0.453 ml |
2.265 ml |
4.53 ml |
| 10 mM |
0.227 ml |
1.133 ml |
2.265 ml |
| 50 mM |
0.045 ml |
0.227 ml |
0.453 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |